ALLMedicine™ Alveolar Soft Part Sarcoma Center
Research & Reviews 100 results
Current Problems in Cancer; O'Sullivan Coyne G, Naqash AR et. al.
Jul 22nd, 2021 - Alveolar Soft Part Sarcoma is one of the less commonly diagnosed soft tissue sarcoma subtypes, an infrequent subtype within the already rare category of human malignancy of sarcoma. In this article we will summarize the histopathological features,...
International Journal of Surgical Pathology; Caporalini C, Giordano F et. al.
Jun 19th, 2021 - Alveolar soft part sarcomas (ASPSs) are rare malignant tumors representing ∼1% of all soft tissue sarcomas. Most ASPS occurring in the central nervous system are metastases. In contrast, primary intracranial ASPSs are extremely rare and only 8 cas...
The Annals of Otology, Rhinology, and Laryngology; Lucas JC, Karadaghy OA et. al.
May 29th, 2021 - Alveolar soft part sarcoma is a rare subset of soft tissue sarcomas, typically presenting in subjects 15 to 35 years of age. Usual presentation sites are the trunk, extremities, and the head and neck. Subjects younger than 5 years are rarely affec...
https://doi.org/10.1007/s00259-021-05388-y 10.1007/s00259-020-04769-z 10.2967/jnumed.119.227967
European Journal of Nuclear Medicine and Molecular Imaging; Zhou X, Wang S et. al.
May 14th, 2021 - Imaging superiority of 68Ga-FAPI-04 over [18F]-FDG PET/CT in alveolar soft part sarcoma (ASPS).|2021|Zhou X,Wang S,Zhu H,Yang Z,Li N,|
https://doi.org/10.1007/s12105-021-01324-6 10.1038/sj.onc.1204074 10.1007/s00428-010-1039-9 10.1016/S0901-5027(00)80054-5 10.1054/bjom.2000.0635 10.1111/j.1365-2303.2009.00694.x 10.1007/s12105-012-0395-y 10.1016/j.joms.2013.10.019 10.1016/j.oooo.2014.12.013 10.1186/s12893-019-0494-8 10.1259/bjr.20130719 10.1097/PAT.0b013e32834d7ba4 10.1097/PAS.0b013e318293729d 10.1093/hmg/5.9.1333 10.1038/modpathol.2011.93 10.2214/AJR.14.12462 10.1111/j.1365-2559.2004.01966.x 10.1136/jcp.2005.031120
Head and Neck Pathology; Hirose K, Naniwa K et. al.
Apr 12th, 2021 - Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma characterized by an alveolar or organoid arrangement of polygonal tumour cells separated by fibrovascular septa. A specific fusion gene [ASPS critical region 1 (ASPSCR1)-TFE3] was det...
Clinicaltrials.gov 4 results
Apr 20th, 2020 - Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS. Little is known with regards to relevan...
Jan 24th, 2019 - Patients aged 16 years and older with a histologically confirmed diagnosis of ASPS will be recruited. Eligible patients will be randomised to receive cediranib (30 mg daily po) or placebo (30 mg daily po) in a 2:1 ratio. At 24 weeks post randomisa...
Oct 17th, 2018 - Background: Alveolar soft part sarcoma is a type of cancer that develops in tissues that connect, support, or surround other organs in the body. It relies heavily on new blood vessels to grow and spread through the body. There is no effective syst...
Feb 8th, 2013 - This is a multi-center, single arm, two-stage phase 2 study of ARQ 197 in patients with microphthalmia transcription factor associated (MiT) tumors. ARQ 197 is a novel small molecule drug designed to block the activity of c-Met, which is thought t...
News 3 results
Oct 23rd, 2018 - Alveolar soft part sarcoma (ASPS) has often proven to be resistant to conventional doxorubicin-based chemotherapy, but tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) may provide new treatment strategies for this rare typ.
Jul 5th, 2006 - Discussion The exact cause of ASPS is not entirely understood; however, studies indicate that genetic alterations may play a role. Certain inherited conditions are associated with an increased risk of developing soft-tissue sarcomas, including Li-...
Jul 5th, 2006 - Introduction Alveolar soft part sarcoma (ASPS), also called alveolar soft-tissue sarcoma (ASTS), is a rare malignant soft-tissue neoplasm, which was first described by Christopherson and colleagues in 1952. Its prevalence is less than 1% of all...